Cytomegalovirus‐associated cerebral sinus vein thrombosis

Sherman, Shany; Justo, Dan; Engel, Tal; Yossepowitch, Orit; Bregman, Noa; Gadoth, Avi; Paran, Yael

doi:10.1002/jmv.23424

Cited by 8 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the associated morbidity and mortality have decreased substantially [ 29 ]. Various organisms, e.g., viruses [ [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] ], tubercular [ 50 , 51 ], bacteria [ [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] ], protozoa and other parasitic infections [ [60] , [61] , [62] , [63] ] have led to the development of CVT. Infection, when considered to be a direct cause of CVT, can spread from structures either adjacent to dura matter (e.g., paranasal sinuses, nose, mastoid and orbit) or from a distant locus.…”

Section: Resultsmentioning

confidence: 99%

Cerebral venous thrombosis in COVID-19

Ghosh

Roy

Mandal

et al. 2021

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

Background and aims Initially, novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) was considered primarily a respiratory pathogen. However, with time it has behaved as a virus with the potential to cause multi-system involvement, including neurological manifestations. Cerebral venous sinus thrombosis (CVT) has increasingly been reported in association with coronavirus infectious disease of 2019 (COVID-19). Here, we have shed light upon CVT and its possible mechanisms in the backdrop of the ongoing COVID-19 pandemic. Methods In this review, data were collected from PubMed, EMBASE and Web of Science, until March 30, 2021, using pre-specified searching strategies. The search strategy consisted of a variation of keywords of relevant medical subject headings and keywords, including “COVID-19”, “SARS-CoV-2”, “coronavirus”, and “cerebral venous sinus thrombosis”. Results COVID-19 has a causal association with a plethora of neurological, neuropsychiatric and psychological effects. CVT has gained particular importance in this regard. The known hypercoagulable state in SARS-CoV-2 infection is thought to be the main mechanism in COVID-19 related CVT. Other plausible mechanisms may include vascular endothelial dysfunction and altered flow dynamics. Conclusions Although there are no specific clinical characteristics, insidious or acute onset headache, seizures, stroke-like, or encephalopathy symptoms in a patient with, or who has suffered COVID-19, should prompt the attending physician to investigate for CVT. The treatment of COVID-19 associated CVT does not differ radically from the therapy of CVT without the infection, i.e. urgent initiation of parenteral unfractionated heparin or low molecular weight heparin followed by conventional or mostly newer oral anticoagulants.

show abstract

Section: Resultsmentioning

confidence: 99%

Cerebral venous thrombosis in COVID-19

Ghosh

Roy

Mandal

et al. 2021

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

show abstract

“…Recognized primarily in immunocompromised patients, such as HIV and renal transplant recipients, CMV mononucleosis has been increasingly recognized as a thrombotic risk factor in immunocompetent patients. To the best of our knowledge to date, there are about 100 case reports, one retrospective case-control, two prospective studies, and one cohort trial reporting local thrombus formation of internal jugular veins, cerebral venous system, and splanchnic, ovarian, iliac, and branch retinal veins [ 3 - 7 ]. The two most common thrombotic events associated with CMV infections are lower-extremity DVT and/or VTE followed by a splanchnic vein thrombosis, such as portal vein thrombosis, superior mesenteric vein thrombosis, inferior mesenteric vein thrombosis, and colic vein thrombosis [ 1 ].…”

Section: Discussionmentioning

confidence: 99%

Venous Thrombosis Secondary to Acute Cytomegalovirus Infection in an Immunocompetent Host: Consideration for New Screening Guidelines

Ngu

Narula

Jilani

et al. 2018

Cureus

View full text Add to dashboard Cite

Serious thrombotic complications associated with an acute cytomegalovirus (CMV) infection in immunocompromised and immunocompetent patients are becoming increasingly recognized. While typically asymptomatic and self-limiting, an acute CMV infection appears to demonstrate a rare propensity for a vascular thrombosis, such as deep vein thrombosis (DVT), thrombophlebitis, and pulmonary embolism (PE). It remains unclear whether other predisposing factors play a role in its pathogenesis. We report the case of a young, immunocompetent male with extensive lower extremity DVT who was coincidentally found to be CMV-immunoglobulin M (IgM) seropositive. In light of the increasing prevalence of CMV-associated thrombotic events, we reviewed the current literature on its incidence, pathophysiology, clinical features, and thrombophilia screening to consider the possibility of CMV seropositivity as an independent risk factor for vascular events. This may have repercussions for screening guidelines and preventive strategies in those with active CMV infection.

show abstract

“…besides, its usefulness is not proved. 27 Overall, 30.1% of patients whom most of them had viremia, and have been treated with antivirals, that is, ganciclovir and/or valganciclovir, 21 , 164 , 168 , 169 Antiviral Agents have been used in Immunocompromised patients more than immunocompetent patients. 142 Some researchers 27 , 170 have reported that they did not apply anticoagulation therapy in patients with CMV‐associated splenic infarcts; however, their patients also had coagulation disorders, such as heterozygous factor V Leiden.…”

Section: Managementmentioning

confidence: 99%

Venous thromboembolism in viral diseases: A comprehensive literature review

Zerangian

Erabi

Poudineh

et al. 2023

Health Science Reports

View full text Add to dashboard Cite

Venous thromboembolism (VTE) is known to be a common respiratory and/or cardiovascular complication in hospitalized patients with viral infections. Numerous studies have proven human immunodeficiency virus infection to be a prothrombotic condition. An elevated VTE risk has been observed in critically ill H1N1 influenza patients. VTE risk is remarkably higher in patients infected with the Hepatitis C virus in contrast to uninfected subjects. The elevation of D‐dimer levels supported the association between Chikungunya and the Zika virus and the rise of clinical VTE risk. Varicella‐zoster virus is a risk factor for both cellulitis and the consequent invasive bacterial disease which may take part in thrombotic initiation. Eventually, hospitalized patients infected with the coronavirus disease of 2019 (COVID‐19), the cause of the ongoing worldwide pandemic, could mainly suffer from an anomalous risk of coagulation activation with enhanced venous thrombosis events and poor quality clinical course. Although the risk of VTE in nonhospitalized COVID‐19 patients is not known yet, there are a large number of guidelines and studies on thromboprophylaxis administration for COVID‐19 cases. This study aims to take a detailed look at the effect of viral diseases on VTE, the epidemiology of VTE in viral diseases, and the diagnosis and treatment of VTE.

show abstract

Cytomegalovirus‐associated cerebral sinus vein thrombosis

Cited by 8 publications

References 11 publications

Cerebral venous thrombosis in COVID-19

Cerebral venous thrombosis in COVID-19

Venous Thrombosis Secondary to Acute Cytomegalovirus Infection in an Immunocompetent Host: Consideration for New Screening Guidelines

Venous thromboembolism in viral diseases: A comprehensive literature review

Contact Info

Product

Resources

About